Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diacylglycerol, Extracellular Vesicles, and Liver Energy Metabolism in Fasting-Induced Insulin Resistance

NCT07928297 is registered in ClinicalTrials.gov with German Diabetes Center as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07928297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Diacylglycerol, Extracellular Vesicles, and Liver Energy Metabolism in Fasting-Induced Insulin Resistance
Lead sponsor
German Diabetes Center
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
July 31, 2028
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

fasting-induced insulin resistance, insulin resistance

Arms

As registered; 2 arms.

  • 60-hour Fasting Experimental60-hour Fasting

    Participants undergo 60 hours of complete fasting under medical supervision. At the end of the fasting period, insulin sensitivity and metabolic responses are assessed using a two-step hyperinsulinemic-euglycemic clamp, stable isotope tracers, magnetic resonance spectroscopy, indirect calorimetry, blood and urine sampling, and skeletal muscle and subcutaneous adipose tissue biopsies.

  • Control (12-hour Overnight Fasting) Active comparator12-hour Overnight Fasting (control)

    Participants undergo a standard 12-hour overnight fast before metabolic assessments, without prolonged fasting. The same principal metabolic and tissue assessments are performed as in the prolonged fasting condition, allowing within-participant comparison of insulin sensitivity, tissue lipid metabolism, and molecular responses.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Skeletal muscle plasma membrane sn-1,2-diacylglycerol content At the end of each study condition in both crossover periods (washout of at least 4 weeks): Day 2 of the control condition, after a 12-hour overnight fast, and Day 4 of the fasting condition, after 60 hours of fasting.

    Difference in plasma membrane-associated sn-1,2-diacylglycerol (DAG) stereoisomer content in skeletal muscle between the 60-hour fasting condition and the control condition, assessed in basal vastus lateralis muscle biopsies.

Lead sponsor's other trials

German Diabetes Center, most recent start first.

Similar trials

Same condition (Insulin Resistance) and phase, most recent start first.